INT307261

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.46
First Reported 2008
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 1.30
Pain Relevance 1.30

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (FABP4) lipid particle (FABP4) nucleus (FABP4)
lipid metabolic process (FABP4) cytoplasm (FABP4)
FABP4 (Homo sapiens)
Pain Link Frequency Relevance Heat
backache 58 100.00 Very High Very High Very High
Lasting pain 7 99.12 Very High Very High Very High
Pain 7 86.20 High High
depression 2 85.12 High High
qutenza 18 82.48 Quite High
Potency 9 56.32 Quite High
withdrawal 1 48.48 Quite Low
imagery 12 42.68 Quite Low
Cannabinoid 3 30.48 Quite Low
Endocannabinoid 12 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Low Back Pain 58 100.00 Very High Very High Very High
Pain 15 99.12 Very High Very High Very High
Anxiety Disorder 3 85.60 High High
Depression 2 85.12 High High
Injury 1 37.88 Quite Low
Recurrence 2 19.04 Low Low
Cancer 4 8.08 Low Low
Sprains And Strains 6 5.00 Very Low Very Low Very Low
Disseminated Intravascular Coagulation 3 5.00 Very Low Very Low Very Low
Nerve Root Compression 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
However, few studies have investigated the efficacy of strategies to prevent ALBP from developing into chronic pain (Newton-John et al 2001).
Spec (investigated) Negative_regulation (prevent) of ALBP associated with lasting pain and backache
1) Confidence 0.46 Published 2008 Journal Journal of pain research Section Body Doc Link PMC3004613 Disease Relevance 1.30 Pain Relevance 1.12
The effect of FABP4 inhibitor [(2?
Negative_regulation (inhibitor) of FABP4
2) Confidence 0.24 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858646 Disease Relevance 0 Pain Relevance 0
CD) (which interferes with AEA cellular uptake by inhibiting the formation of membrane lipid rafts [23], [24] and 4) oleic acid (OA) and the specific FABP4 inhibitor [(2?
Negative_regulation (inhibitor) of FABP4
3) Confidence 0.24 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858646 Disease Relevance 0 Pain Relevance 0.15
The effect of PCL-NP-AEA was also dramatically less sensitive to oleic acid or the FABP4 inhibitor [(2?
Negative_regulation (inhibitor) of FABP4
4) Confidence 0.24 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858646 Disease Relevance 0 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox